Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

NCT06811844 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

208

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Neoplasms
PD-1 Inhibitor
Induction Therapy
Complete Response
Chemotherapy

Interventions

DRUG: Two-cycle induction chemotherapy + immunotherapy
DRUG: Three-cycle induction chemotherapy + immunotherapy

Sponsor

The First Affiliated Hospital of Xiamen University